M. Saleem Ismail, M.D.

Academic and Clinical Appointments

Senior Instructor in Psychiatry

Contact Information

Alzheimer’s Disease, Care, Research and Education Program
Monroe Community Hospital
435 East Henrietta Road
Rochester, New York 14620

Phone: (585) 760-6593
Fax: (585) 760-6572


Saleem_Ismail@urmc.rochester.edu

Education

Sind Medical College/University of Karachi,
                                    Karachi, Pakistan
                                    MBBS (M.D. equivalent)

Resident in Adult Psychiatry at the Medical College of Pennsylvania in Philadelphia
Fellow in Geriatric Psychiatry at the University of Rochester in New York.

Research Focus
and Interests

Selected Publications

ORIGINAL ARTICLES

Ismail MS, Dagerman K, Tariot PN, Abbott S, Kavanagh S, Schneider LS.  National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness- Alzheimer’s Disease (CATIE-AD): Description of Baseline Participant Characteristics.  Current Alzheimer’s Research 2007 (in press).

ADAPT Research Group . Cardiovascular and Cerebrovascular Events in the Randomized, Controlled Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT). Neurology 2007.

ADAPT Research Group . No immediate reduction in Alzheimer’s disease incidence with naproxen or celecoxib: Results from ADAPTized, Controlled Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT). PLoS Clinical trials November 2006;1(7):e33. doi:10.1371/journal.pctr.0010033

Lon S. Schneider, M.D., Pierre N. Tariot, M.D., Karen S. Dagerman, Sonia Davis, Dr.P.H., John Hsiao, M.D., M. Saleem Ismail, MD, Barry D. Lebowitz, Ph.D., Constantine G. Lyketsos, M.D., J. Michael Ryan, M.D., T. Scott Stroup, M.D., David L. Sultzer, M.D., Daniel Weintraub, M.D., Jeffrey A. Lieberman, M.D. for the CATIE-AD Study Group:  Effectiveness of Atypical Antipsychotics Drugs in Patients with Alzheimer’s Disease.  N Eng J Med 35:15 October 12, 2006.

Schneider LS, Ismail MS, Dagerman K, Davis S, Olin J, McManus D, Pfeiffer E, Ryan JM, Sultzer DL, and Tariot PN* For the Alzheimer’s Disease Trial Center Members. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer’s Disease Trial.  Schizophrenia Bulletin, 29(1)57-72,2003.

Ismail MS, Richard IH.  A Reality Test: How Well Do We Understand Psychosis in Parkinson’s Disease?  J Neuropsychiatry Clinical Neurosciences 16(1):8-18, Winter 2004.

BOOKS, MONOGRAPHS, BOOK CHAPTERS AND REVIEW ARTICLES

Tariot PN, Daiello LA, Ismail MS: Treatment of agitation, aggression, and behavioral disturbances in dementia.  CME Monograph.  Access Medical Group, Arlington Heights, Illinois.  March 1, 2002.

Ismail MS, Tariot PN.  Alzheimer’s Disease: Bridging the Gap Between Clinical Trials and Clinical Practice.  Practical Neurology 2002;1(8):30-35. 

Ismail MS, Tariot PN.  Alzheimer’s Disease: A Step-by-Step Approach to Clinical Diagnosis and Treatment.   Practical Neurology 2002;1(9):25-29.

Tariot PN, Ismail MS.  Cholinesterase Inhibitors.  Practical Guide to Therapeutic Drugs: Practical Neurology 2002;(S):47-49.

Tariot PN, Ismail MS.  A 5- year Review of Quetiapine.  Journal of Clinical Psychiatry 2002;63(S13): 21-26.

Tariot PN, Loy R, Ryan JM, Porsteinsson A, Ismail S.  Mood Stabilizers in Alzheimer’s Disease: Symptomatic and Neuroprotective Rationales.  Advance Drug Delivery Reviews.  2002;54:1567-1577.

Ismail MS, Tariot PN.  Long-Term Benefits of Early Pharmacologic Treatment in Alzheimer’s Disease.  Essential Psychopharmacology 2003;5(2):71-82.

Porsteinsson A, Ryan JM, Ismail MS, Tariot PN. Non-Psychotic Behavioral Disturbance in Dementia.  Handbook of Dementia: Psychological, Psychiatric and Neurological Perspectives pp. 335-357. Lichtenberg PA, Murman DL, Mellow AM (eds).  John Wiley & Sons Inc., Hoboken, New Jersey, 2003.

Ismail MS, Tariot,PN.  Galantamine in Treatment of Alzheimer’s Disease.  In Alzheimer’s Disease: A Physician’s Guide to Practical Management pp 193-202. Ralph W. Richter, Brigitte Z. Richter (eds).  Humana Press Inc., Totowa, NJ 2003.

Tariot PN, Profenno LA, Ismail MS. Efficacy of Atypical Antipsychotics in Elderly Patients with Dementia.  J Clin Psychiatry 2004;65(S 11):11-15.

Porsteinsson AP, Ismail MS.  Memantine: A Novel Therapeutic Option for Alzheimer’s Disease. Today’s Therapeutic Trends 22(1):17-28, 2004.

Ismail MS.  New Directions in Psychotic Disorders: Clinical simulations in the management of the patient with schizophrenia in community and long-term care settings.  Intermed Press, Darien, Connecticut, January 2004.

Profenno LA, Tariot PN, Ismail MS. Treatments for Behavioral and Psychological Symptoms in Alzheimer’s Disease and Other Dementias. In Dementia-3rd Edition pp. 482-498.  Alistair Burns, John O’Brien & David Ames (eds). Edward Arnold Limited., London 2005.

Boyle L, Ismail MS, Porsteinsson AP. The Dementia Work-up.  In Principles and Practice of Geriatric Psychiatry pp. 137-152. Marc Agronin & Gabe J. Maletta (eds). Lippincott, Williams and Wilkins, Philadelphia 2006.

LETTERS, EDITORIALS, SHORT ARTICLES AND OTHER

Ismail MS, Dagerman KS, Schneider LS.  Implementing Effectiveness Trials:  A CATIE Experience. [Abstract] Journal of Clinical Psychiatry 2002;63(11):1066-1067.

Ismail MS.  Publication Charges [Letter].  Pak J Med Sci. 2002;18(3) 264.

Ismail MS, Schneider LS, Dagerman KS, Davis S, Tariot PN. NIMH atypical antipsychotic effectiveness trial in Alzheimer’s disease (CATIE AD): what we have learned so far. [Abstract] 16th Annual Meeting American Association Geriatric Psychiatry, Honolulu, Hawaii. March 1-4, 2003. Proceedings of the 16th Annual Meeting of the American Association for Geriatric Psychiatry.

Ismail MS, Schneider LS, Dagerman KS, Davis S, Tariot PN. NIMH atypical antipsychotic effectiveness trial in Alzheimer’s disease (CATIE AD): An update (CR 65).  156th Annual Meeting of the American Psychiatric Association, San Francisco California, May 17-23, 2003.

Ismail MS, Schneider LS, Dagerman KS, Davis S, Tariot PN. NIMH atypical antipsychotic effectiveness trial in Alzheimer’s disease (CATIE AD): An update. [Abstract] NCDEU 43rd Annual Meeting, Boca Raton, Florida, May 27-30, 2003.

Schneider LS, Ismail, MS, Dagerman KS.  Comparative Effectiveness of Antipsychotic Medications in Patients with Alzheimer’s Disease (CATIE – AD): Progress Report (S078-005).  IPA 11th International Congress, Chicago, Illinois, August 17-21, 2003.  International Psychogeriatrics, 15 (suppl 2): 165, 2003.

Schneider LS, Dagerman KS, Ismail MS, Davis S, Tariot PN. Comparative Effectiveness of Antipsychotic Medications in Alzheimer’s Disease (CATIE-AD):  A Preliminary Report on Clinical Course. [Abstract] 17th Annual Meeting American Association Geriatric Psychiatry, Baltimore, Maryland. February 21-24, 2004.

 Ismail MS, Schneider LS, Dagerman KS, Davis S, Tariot PN. Clinical Course of CATIE Patients.  [Poster] NCDEU 44th Annual Meeting, Phoenix, Arizona, June 1-4, 2004

Ismail MS, Schneider LS, Dagerman KS, Davis S, Tariot PN. NIMH Comparative Effectiveness of Antipsychotic Medications in Patients with Alzheimer’s disease (CATIE – AD): Clinical course. [Poster] The 9th International Conference on Alzheimer’s Disease and Related Disorders, Philadelphia, Pennsylvania. July 17-22, 2004 (Poster).